Li Wei-Ya, Li Hong-De, Peng Shi-Qin, Li Jun-Li, Chen Mao
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
J Chin Med Assoc. 2024 Nov 15. doi: 10.1097/JCMA.0000000000001191.
Since the first transcatheter aortic valve replacement (TAVR) was performed in China in 2010, TAVR has developed rapidly. However, the temporal trends in the 1-year prognosis after TAVR in China have not been described. This study enrolled patients treated at a high-volume Chinese TAVR center, West China Hospital, between 2015 and 2022, to analyze and characterize the temporal trends in 1-year outcomes. After multivariate adjustment, the 30-day mortality, 1-year all-cause mortality, 1-year cardiac mortality, and 1-year permanent pacemaker implantation rates showed a significantly decreasing trend (adjusted p for trend < 0.05). The 1-year major adverse cardiovascular event and 1-year stroke incident rate also decreased but did not reach significance. In conclusion, this study, for the first time, reveals a declining trend in adverse prognosis among patients who underwent TAVR in China.
自2010年中国首例经导管主动脉瓣置换术（TAVR）开展以来，TAVR发展迅速。然而，中国TAVR术后1年预后的时间趋势尚未得到描述。本研究纳入了2015年至2022年期间在中国大容量TAVR中心华西医院接受治疗的患者，以分析和描述1年结局的时间趋势。经过多变量调整后，30天死亡率、1年全因死亡率、1年心脏死亡率和1年永久起搏器植入率呈显著下降趋势（趋势调整p<0.05）。1年主要不良心血管事件和1年卒中发生率也有所下降，但未达到显著水平。总之，本研究首次揭示了中国接受TAVR治疗患者不良预后呈下降趋势。
